Semaglutide Launch: Domestic companies launch semaglutide jabs at affordable prices

NEW DELHI: Several home companies together with Sun Pharma, Torrent, Zydus, Dr Reddy’s, Glenmark and Alkem introduced the launch of semaglutide on Day 1, considerably reducing the price of weight-loss remedy.This is within the wake of the innovator Novo Nordisk dropping its patent on semaglutide on March 20.Sun Pharma’s weekly remedy prices, from initiation to the best dose, ranges from roughly Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity, supporting higher affordability, the corporate stated in a press release.Kirti Ganorkar, managing director, Sun Pharma stated, “To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey”.Further, Torrent Pharma has launched each oral and injectable formulations, increasing its presence in metabolic issues comparable to type-2 diabetes and weight problems. “We are proud to be the primary Indian firm to supply this remedy throughout oral and injectable formulations, giving healthcare professionals a holistic selection for treating sufferers”, Amal Kelshikar, CEO – India Business, Torrent Pharma stated.Others like USV introduced the launch in collaboration with Dr Reddy’s Labs. The flurry of launches displays a broader push by companies to faucet into India’s quickly increasing metabolic issues market.Blockbuster weight-loss therapies –Wegovy and Mounjaro, marketed by Novo Nordisk and Eli Lilly respectively, have been launched at ‘’India-specific prices’’ final 12 months, whereas the worldwide bestseller Ozempic by the Dutch agency, made its India debut solely in December final 12 months. Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, helps to regulate blood sugar and enhance satiety, decreasing cravings for meals, ultimately inducing weight-loss.These launches come at the same time as India faces an escalating diabetes burden, with over 100 million folks at present residing with diabetes.